Despite of the high cost of single testing, p16INK4a/Ki-67 dual immunocytochemistry could be cost-effective in long term perspectives, as it has been shown to be helpful in triaging of ASC/LSIL categories and reducing the health and financial problems caused by underling invasive cancer, as well as by unnecessary invasive tests. This evidence concerns the gene CDKN2A and cancer.